The Luna SARS-CoV-2 RT-qPCR Multiplex Assay Kit is optimized for real-time qualitative detection of SARS-CoV-2 nucleic acid using hydrolysis probes. In a single tube, RNA is first converted to cDNA by a reverse transcriptase, then a DNA-dependent DNA polymerase amplifies the cDNA, enabling quantitation via real-time or quantitative PCR (qPCR). Probe-based qPCR/RT-qPCR monitors an increase in fluorescence upon 5′→3′ exonuclease cleavage of a quenched, target-specific probe to measure DNA amplification at each PCR cycle. At a point where the fluorescence signal is confidently detected over the background fluorescence, a quantification cycle or Cq value can be determined. Cq values can be used to evaluate relative target abundance between two or more samples.Figure 1: Luna SARS-CoV-2 RT-qPCR Multiplex Assay Kit componentsFigure 2: The Luna SARS-CoV-2 RT-qPCR Multiplex Assay Kit detects two regions of the N gene and the human RNase P gene in a single reactionA. The two SARS-CoV-2 sequences are based on those provided by the CDC, but modified to contain different fluorophores (N1: HEX, N2: FAM).B. The RNase P internal control includes a Cy5 labeled probe and a re-designed reverse primer. This primer spans an exon-exon junction to avoid amplification of human genomic DNA which contains a 2.4 kb intron.The SARS-CoV-2 Primer/Probe Mix contains primers and probes specific to two regions of the SARS-CoV-2 virus N gene [based on sequences provided by the Centers for Disease Control and Prevention (CDC)]. The probes have been modified to contain different fluorophores (N1: HEX; N2: FAM) to enable simultaneous observation on two different channels of a real-time instrument. To ensure the integrity of the input material and absence of inhibition, an internal control (IC) primer and probe set, designed to amplify the human RNase P gene, is also included in the primer mix. The reverse primer of this target has been modified from the CDC design to target an exon/exon boundary to reduce background amplification from possible contaminating genomic DNA. Amplification of the IC is observed in the Cy5 channel. A positive control (PC) template (SARS-CoV-2 N gene cloned into a plasmid) is also provided.The Luna Probe One-Step RT-qPCR 4X Mix with UDG (NEB #M3019) included in the kit enables higher amounts of input material and supports sample pooling strategies, with minimal loss of sensitivity or specificity. It contains all necessary components for one-step RT-qPCR and is formulated with a unique passive reference dye that is compatible across a variety of instrument platforms, including those that require a high or low ROX reference signal. The reaction mix also features thermolabile UDG and dUTP for carryover prevention and a non-fluorescent visible tracking dye for monitoring reaction setup. This visible dye does not overlap spectrally with fluorophores commonly used in qPCR and does not interfere with real-time detection.Figure 3: The Luna SARS-CoV-2 RT-qPCR Multiplex Assay Kit demonstrates a lower limit of detection than TaqPath™1-Step RT-qPCR Master Mix, CGLOD comparison using: Luna SARS-CoV-2 RT-qPCR Multiplex Assay Kit for multiplex RT-qPCR targeting 2019-nCoV_N1 target (HEX) and 2019-nCoV_N2 target (FAM), according to reaction and cycling conditions provided in the E3019 product manual, and TaqPath 1-Step RT-qPCR Master Mix, CG for singleplex RT-qPCR targeting 2019-nCoV_ N1 (FAM) and 2019-nCoV_N2 (FAM), according to the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel guidelines. Performance was evaluated using Synthetic Twist SARS-CoV-2 RNA Control 2 diluted in 10 ng of Jurkat total RNA. Data was collected on an Applied Biosystems® 7500 Fast real-time instrument (96-well, 20 µl reactions). Under these conditions, the Luna Kit has an LOD of 5 copies/reaction for both targets while the LOD using TaqPath is 10 copies/reaction for these targets.Figure 4: Luna SARS-CoV-2 RT-qPCR Multiplex Assay kit enables sample pooling of purified RNAA pool containing five samples was prepared by combining 2 µl of one mock positive (10 copies of the Twist Synthetic SARS-CoV-2 RNA Control diluted in 10 ng of Jurkat total RNA) and 2 µl each of 4 mock negative samples (10 ng Jurkat total RNA only). Multiplex performance for the pooled sample (10 µl) was compared to an individual sample (2 µl, a total of 10 copies of N gene and 10 ng of Jurkat total RNA). Data was collected on an Applied Biosystems 7500 Fast Real-Time instrument (96-well, 20 µl reactions). The amplification curves for the N1 and N2 targets indicate similar Cq values from a positive sample whether assayed individually or as part of a pool. As expected, the RNase P signal from the pooled sample has an earlier Cq compared to the single sample since it contains 5 times the amount of human total RNA.Figure 5: Limit of Detection (LOD) of the Luna SARS-CoV-2 RT-qPCR Multiplex Assay KitThe Luna SARS-CoV-2 RT-qPCR LOD was determined by multiplex RT-qPCR targeting 2019-nCoV_N1 (HEX) and 2019-nCoV_N2 (FAM) from various control samples of SARS-CoV-2 RNA. Performance was evaluated using (A) Twist Synthetic SARS-CoV-2 RNA Control 2 diluted in 10 ng of Jurkat total RNA. Data was collected by two users on Applied Biosystems (ABI) 7500 Fast Real-Time instrument, ABI QuantStudio™ 6 Flex Real-Time PCR system, and Bio-Rad CFX instrument (96-well, 20 µl reactions). The LOD for the Twist RNA is 5 copies/reaction on all three instruments. Performance was also evaluated using (B) Genomic SARS-CoV-2 RNA from ATCC (ATCC® VR-1986D™), NIST (Fragment 1 – Includes SARS-CoV-2 sequence: 25949-29698 of isolate USA-WA1/2020), and SeraCare AccuPlex™ SARS-CoV-2 Verification Panel V2 (0505-0132) RNA extracted with Monarch Total RNA Miniprep Kit (NEB# T2010). All RNA samples in this panel were diluted in 10 ng of Jurkat total RNA and tested on an ABI 7500 Fast Real-Time instrument. The LOD is 2.5 GE (genomic copy equivalent) for the SARS-CoV-2 genomic RNA from ATCC, 1x107-fold dilution for the NIST SARS-CoV-2 Test Material and 15 copies for the SeraCare AccuPlex reference material (assuming 100% recovery of input material from the RNA extraction procedure).Figure 6: Improved performance on the SARS-CoV-2 N2 target from the Luna Probe One-Step RT-qPCR 4X Mix with UDG compared to the TaqPath 1-Step RT-qPCR Master Mix, CGA. Singleplex RT-qPCR targeting 2019-nCoV_1 (HEX) and 2019-nCoV_N2 (FAM) was performed using the Luna Probe One-Step RT-qPCR 4X Mix with UDG, according to reaction and cycling conditions provided in the E3019 product manual.B. Singleplex RT-qPCR targeting 2019-nCoV_N1 (FAM) and 2019-nCoV_N2 (FAM) was performed using TaqPath 1-Step RT-qPCR Master Mix, CG, as outlined in the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel guidelines. Performance was evaluated over a 5-log range of Twist Synthetic SARS-CoV-2 RNA Control 2 diluted in 10 ng of Jurkat total RNA. Data was collected on an Applied Biosystems 7500 Fast Real-Time instrument (96-well, 20 µl reactions). Under these conditions, both Luna and TaqPath mixes perform well with the N1 target. For the N2 target, even though 10 copies is in a detectable range for the TaqPath mix, substandard linearity is consistently observed, while the Luna mix exhibits strong linearity and faster Cq’s.The Luna Probe One-Step RT-qPCR 4X Mix with UDG features Hot Start Taq DNA Polymerase combined with a novel WarmStart-activated reverse transcriptase, allowing dual control of enzyme activity via reversible, aptamer-based inhibition. This temperature-dependent activation helps to prevent undesirable non-specific priming and extension prior to thermocycling, providing added security for setting up reactions at room temperature. The engineered WarmStart Luna Reverse Transcriptase also possesses higher thermostability than many other RTs, allowing an optimal reaction temperature of 55°C.Figure 7: Room temperature stability of Luna RT-qPCR Mix enables workflow flexibilitySingleplex (SP) and multiplex (MP) RT-qPCR targeting 2019-nCoV_N1 (HEX) and 2019-nCoV_N2 (FAM) was performed using the Luna Probe One-Step RT-qPCR 4X Mix with UDG, according to reaction and cycling conditions provided in the NEB #E3019 product manual. Singleplex RT-qPCR targeting 2019-nCoV_N1 (FAM) and 2019-nCoV_N2 (FAM) was performed using TaqPath 1-Step RT-qPCR Master Mix, CG, according to the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel guidelines. Performance was evaluated over a 5-log range (100,000-10 copies) of Synthetic SARS-CoV-2 RNA Control 2 diluted in 10 ng of Jurkat total RNA. RT-qPCR reactions were incubated at room temperature for 0, 2, 5 and 24 hours before running on an Applied Biosystems 7500 Fast real-time instrument (96-well, 20 μl reactions). Using synthetic Twist RNA, consistent performance is observed with up to 24 hours of room temperature incubation with the Luna probe One-Step RT-qPCR Mix, while TaqPath showed a Cq delay ≥1 at 2 hours with declining performance as incubation time increased.
This product is related to the following categories:
Luna® qPCR & RT-qPCR Products,
PCR, qPCR & Amplification Technologies Products
This product can be used in the following applications:
qPCR & RT-qPCR,
RT-qPCR, RT-PCR and cDNA Synthesis
品牌介绍
New England Biolabs(NEB)公司 NEB公司——三十多年的卓越品质NEB公司成立于二十世纪七十年代中期,拥有众多经验丰富的科学家,是生产生命科学试剂的领导者。目前,NEB为基因组研究提供最齐全的重组酶和天然酶,并且公司业务范围已延伸至蛋白质组学和药品开发领域。回顾三十余年来的历程,NEB公司作为先驱公司之一,为促进生物科技工业的发展做出了巨大的贡献。NEB美国总部乔迁新址后拥有最尖端的设备,有一座现代化的发酵中心及设备齐全的实验室,这些实验室主要用于产品生产、质量监控、产品开发和基础科研之用。作为首批以商业规模生产限制性内切酶的公司之一,NEB一直专注于内切酶的研究,并保持业内领先水平。NEB公司一贯坚持以科学为本的原则,公司生产的试剂因其高质量、高性价比享誉世界。重组酶NEB公司对酶的生产与其基础科研不能分开,通过对限制/修饰系统的克隆和过量表达方面的研究,使我们能够大大降低成本,改善产品质量。NEB已经成功克隆了180多种内切酶,其中大多是完全克隆,少数是部分克隆。目前,NEB可供应240多种内切酶,其中180多种可以重组酶形式提供,同时还有大量的应用途广泛的重组聚合酶和重组修饰酶。质量与客户服务NEB公司凭借着严格的质检程序、深入的基础科研以及不断开发的研发项目,承诺为全球科技人员提供高纯度的科研产品。直接与NEB总部联系或与NEB的国际网点联系,即可体验到NEB的个性化客户服务。公司内负责生产以及负责进行质量监控的科学家(产品负责人)也就是技术支持人员。他们为客户解答有关限制核酸内切酶、甲基化酶、以及其他DNA修饰酶、蛋白质修饰酶方面的问题。同时,公司的有机合成部门可提供linkers、引物、adaptors、探针以及寡核苷酸合成等方面的信息。研究人员也可为客户提供技术支持服务,这些研究人员在DNA测序、甲基化、克隆、过量表达、发酵、蛋白质纯化以及蛋白质分析方面都有很深造诣。基础科研NEB在分子生物学和寄生虫学方面的基础研究由公司内部的资深科学家负责。这些科学家在他们各自的领域都卓有成绩,经常在业内著名杂志上发表文献,指导博士后工作、为大学生提供暑期实习机会,而且经常受邀去当地学校进行演讲。NEB鼓励公司与外界合作,每周学术探讨会为其他科学家们提供了交流和展示的平台。环保政策NEB公司在资助科研项目时最基本原则之一就是:一切工作都应符合保护生态环境。公司产品生产、分析以及运输过程既要满足产品的稳定性,也要符合我们的环保政策。20年来,NEB公司最引人注目的一项环保政策是:回收运输泡沫盒,虽然这项工作首创于美国,但是,目前加拿大、德国以及英国的分公司也同样实施了。公司还在内部开展多方位的回收工作,经常用再生纸张印刷市场宣传资料。这些小细节不会影响产品质量,但是对环境的保护却是显而易见。公司职责除环保政策外,通过基金会,NEB还竭力为改善当地社区及全人类尽微薄之力。NEB基金会创立于1982年,属私人性质,其宗旨是支持发展中国家的环保、教育、健康及艺术事业。此外,NEB捐款委员会也经常向当地社区进行捐款活动。